- Home
- CYCN vs LIXT Comparison
CYCN vs LIXT Comparison
Compare CYCN & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- LIXT
- Stock Information
- Founded
- CYCN 2018
- LIXT 2005
- Country
- CYCN United States
- LIXT United States
- Employees
- CYCN N/A
- LIXT N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- CYCN Health Care
- LIXT Health Care
- Exchange
- CYCN Nasdaq
- LIXT Nasdaq
- Market Cap
- CYCN 11.8M
- LIXT 12.4M
- IPO Year
- CYCN N/A
- LIXT N/A
- Fundamental
- Price
- CYCN $2.17
- LIXT $4.98
- Analyst Decision
- CYCN
- LIXT
- Analyst Count
- CYCN 0
- LIXT 0
- Target Price
- CYCN N/A
- LIXT N/A
- AVG Volume (30 Days)
- CYCN 58.6K
- LIXT 218.7K
- Earning Date
- CYCN 08-05-2025
- LIXT 08-07-2025
- Dividend Yield
- CYCN N/A
- LIXT N/A
- EPS Growth
- CYCN N/A
- LIXT N/A
- EPS
- CYCN N/A
- LIXT N/A
- Revenue
- CYCN $2,174,000.00
- LIXT N/A
- Revenue This Year
- CYCN N/A
- LIXT N/A
- Revenue Next Year
- CYCN N/A
- LIXT N/A
- P/E Ratio
- CYCN N/A
- LIXT N/A
- Revenue Growth
- CYCN N/A
- LIXT N/A
- 52 Week Low
- CYCN $1.27
- LIXT $0.64
- 52 Week High
- CYCN $9.47
- LIXT $5.14
- Technical
- Relative Strength Index (RSI)
- CYCN 32.29
- LIXT 67.50
- Support Level
- CYCN $2.51
- LIXT $4.20
- Resistance Level
- CYCN $2.41
- LIXT $5.14
- Average True Range (ATR)
- CYCN 0.25
- LIXT 0.46
- MACD
- CYCN -0.07
- LIXT -0.01
- Stochastic Oscillator
- CYCN 3.48
- LIXT 89.40
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.